BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kollb-Sielecka M, Demolis P, Emmerich J, Markey G, Salmonson T, Haas M. The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the Committee for Medicinal Products for Human Use. Sleep Med 2017;33:125-9. [PMID: 28449891 DOI: 10.1016/j.sleep.2017.01.002] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Lecendreux M, Plazzi G, Franco P, Jacqz-aigrain E, Robert P, Duvauchelle T, Schwartz J. Pharmacokinetics of pitolisant in children and adolescents with narcolepsy. Sleep Medicine 2020;66:220-6. [DOI: 10.1016/j.sleep.2019.10.024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
2 Ghamari N, Kouhi Hargelan S, Zivkovic A, Leitzbach L, Dastmalchi S, Stark H, Hamzeh-Mivehroud M. Guided rational design with scaffold hopping leading to novel histamine H3 receptor ligands. Bioorg Chem 2021;117:105411. [PMID: 34653944 DOI: 10.1016/j.bioorg.2021.105411] [Reference Citation Analysis]
3 Ghamari N, Zarei O, Arias-Montaño JA, Reiner D, Dastmalchi S, Stark H, Hamzeh-Mivehroud M. Histamine H3 receptor antagonists/inverse agonists: Where do they go? Pharmacol Ther 2019;200:69-84. [PMID: 31028835 DOI: 10.1016/j.pharmthera.2019.04.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
4 Plancoulaine S, Guyon A, Inocente CO, Germe P, Zhang M, Robert P, Lin JS, Franco P. Cerebrospinal Fluid Histamine Levels in Healthy Children and Potential Implication for SIDS: Observational Study in a French Tertiary Care Hospital. Front Pediatr 2022;10:819496. [PMID: 35450108 DOI: 10.3389/fped.2022.819496] [Reference Citation Analysis]
5 Wágner G, Mocking TAM, Arimont M, Provensi G, Rani B, Silva-Marques B, Latacz G, Da Costa Pereira D, Karatzidou C, Vischer HF, Wijtmans M, Kieć-Kononowicz K, de Esch IJP, Leurs R. 4-(3-Aminoazetidin-1-yl)pyrimidin-2-amines as High-Affinity Non-imidazole Histamine H3 Receptor Agonists with in Vivo Central Nervous System Activity. J Med Chem 2019;62:10848-66. [PMID: 31675226 DOI: 10.1021/acs.jmedchem.9b01462] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
6 Romigi A, Vitrani G, Lo Giudice T, Centonze D, Franco V. Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy. Drug Des Devel Ther 2018;12:2665-75. [PMID: 30214155 DOI: 10.2147/DDDT.S101145] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 5.3] [Reference Citation Analysis]
7 Jończyk J, Malawska B, Bajda M. Hybrid approach to structure modeling of the histamine H3 receptor: Multi-level assessment as a tool for model verification. PLoS One 2017;12:e0186108. [PMID: 28982153 DOI: 10.1371/journal.pone.0186108] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
8 Setnik B, McDonnell M, Mills C, Scart-Grès C, Robert P, Dayno JM, Schwartz JC. Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy. Sleep 2020;43:zsz252. [PMID: 31626696 DOI: 10.1093/sleep/zsz252] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
9 Hanin C, Arnulf I, Maranci JB, Lecendreux M, Levinson DF, Cohen D, Laurent-Levinson C. Narcolepsy and psychosis: A systematic review. Acta Psychiatr Scand 2021;144:28-41. [PMID: 33779983 DOI: 10.1111/acps.13300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ma X, Gao M, Vischer HF, Leurs R. A NanoBRET-Based H3R Conformational Biosensor to Study Real-Time H3 Receptor Pharmacology in Cell Membranes and Living Cells. Int J Mol Sci 2022;23:8211. [PMID: 35897787 DOI: 10.3390/ijms23158211] [Reference Citation Analysis]
11 Hussami AA, Guillet C, Aravantinos D, Girod JC, Lemesle-Martin M. Severe insomnia with nightmares. Rev Neurol (Paris) 2021:S0035-3787(21)00451-3. [PMID: 33892924 DOI: 10.1016/j.neurol.2020.10.014] [Reference Citation Analysis]
12 Cevikbas F, Lerner EA. Physiology and Pathophysiology of Itch. Physiol Rev 2020;100:945-82. [PMID: 31869278 DOI: 10.1152/physrev.00017.2019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
13 Mocking TAM, Buzink MCML, Leurs R, Vischer HF. Bioluminescence Resonance Energy Transfer Based G Protein-Activation Assay to Probe Duration of Antagonism at the Histamine H3 Receptor. Int J Mol Sci 2019;20:E3724. [PMID: 31366084 DOI: 10.3390/ijms20153724] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
14 Shirley DW, Sterrett J, Haga N, Durham C. The therapeutic versatility of antihistamines: A comprehensive review. Nurse Pract 2020;45:8-21. [PMID: 31913218 DOI: 10.1097/01.NPR.0000651112.76528.ed] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Hauwert NJ, Mocking TAM, Da costa pereira D, Lion K, Huppelschoten Y, Vischer HF, De esch IJP, Wijtmans M, Leurs R. A Photoswitchable Agonist for the Histamine H 3 Receptor, a Prototypic Family A G‐Protein‐Coupled Receptor. Angew Chem 2019;131:4579-83. [DOI: 10.1002/ange.201813110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
16 Abad VC. An evaluation of sodium oxybate as a treatment option for narcolepsy. Expert Opinion on Pharmacotherapy 2019;20:1189-99. [DOI: 10.1080/14656566.2019.1617273] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Guevarra JT, Hiensch R, Varga AW, Rapoport DM. Pitolisant to Treat Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy: Rationale and Clinical Utility. Nat Sci Sleep 2020;12:709-19. [PMID: 33117007 DOI: 10.2147/NSS.S264140] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
18 Davis CW, Kallweit U, Schwartz JC, Krahn LE, Vaughn B, Thorpy MJ. Efficacy of pitolisant in patients with high burden of narcolepsy symptoms: pooled analysis of short-term, placebo-controlled studies. Sleep Med 2021;81:210-7. [PMID: 33721598 DOI: 10.1016/j.sleep.2021.02.037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
19 Lamb YN. Pitolisant: A Review in Narcolepsy with or without Cataplexy. CNS Drugs 2020;34:207-18. [PMID: 31997137 DOI: 10.1007/s40263-020-00703-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
20 Franceschini C, Pizza F, Antelmi E, Folli MC, Plazzi G. Narcolepsy treatment: pharmacological and behavioral strategies in adults and children. Sleep Breath 2020;24:615-27. [PMID: 31290083 DOI: 10.1007/s11325-019-01894-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
21 Pennington S, Stutzman D, Sannar E. Pitolisant in an Adolescent with Prader-Willi Syndrome. J Pediatr Pharmacol Ther 2021;26:405-10. [PMID: 34035686 DOI: 10.5863/1551-6776-26.4.405] [Reference Citation Analysis]
22 Nirogi R, Mudigonda K, Bhyrapuneni G, Muddana NR, Shinde A, Goyal VK, Pandey SK, Mohammed AR, Ravula J, Jetta S, Palacharla VRC. Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses. Clin Drug Investig 2020;40:603-15. [DOI: 10.1007/s40261-020-00920-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
23 Thorpy MJ, Shapiro C, Mayer G, Corser BC, Emsellem H, Plazzi G, Chen D, Carter LP, Wang H, Lu Y, Black J, Dauvilliers Y. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol 2019;85:359-70. [PMID: 30694576 DOI: 10.1002/ana.25423] [Cited by in Crossref: 69] [Cited by in F6Publishing: 44] [Article Influence: 34.5] [Reference Citation Analysis]
24 Li S, Yang J. Pitolisant for treating patients with narcolepsy. Expert Review of Clinical Pharmacology 2020;13:79-84. [DOI: 10.1080/17512433.2020.1714435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
25 Flick AC, Ding HX, Leverett CA, Fink SJ, O’donnell CJ. Synthetic Approaches to New Drugs Approved During 2016. J Med Chem 2018;61:7004-31. [DOI: 10.1021/acs.jmedchem.8b00260] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
26 Franceschini C, Pizza F, Cavalli F, Plazzi G. A practical guide to the pharmacological and behavioral therapy of Narcolepsy. Neurotherapeutics 2021;18:6-19. [PMID: 33886090 DOI: 10.1007/s13311-021-01051-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Krishnamurti C. H3 antagonists and postoperative cognitive dysfunction. J Anaesthesiol Clin Pharmacol 2019;35:157-60. [PMID: 31303701 DOI: 10.4103/joacp.JOACP_141_18] [Reference Citation Analysis]
28 Molenhuis RT, Hutten L, Kas MJH. Histamine H3 receptor antagonism modulates autism-like hyperactivity but not repetitive behaviors in BTBR T+Itpr3tf/J inbred mice. Pharmacol Biochem Behav 2021;212:173304. [PMID: 34856309 DOI: 10.1016/j.pbb.2021.173304] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Łażewska D, Kieć-Kononowicz K. Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017). Expert Opin Ther Pat 2018;28:175-96. [PMID: 29334795 DOI: 10.1080/13543776.2018.1424135] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
30 Tiligada E, Ennis M. Histamine pharmacology: from Sir Henry Dale to the 21st century. Br J Pharmacol 2020;177:469-89. [PMID: 30341770 DOI: 10.1111/bph.14524] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 8.5] [Reference Citation Analysis]
31 de Biase S, Pellitteri G, Gigli GL, Valente M. Evaluating pitolisant as a narcolepsy treatment option. Expert Opin Pharmacother 2021;22:155-62. [PMID: 32941089 DOI: 10.1080/14656566.2020.1817387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
32 Poyurovsky M, Weizman A. Beneficial Effect of Betahistine, a Structural Analog of Histamine, in Clozapine-Related Sedation. Clin Neuropharm 2019;42:145-145. [DOI: 10.1097/wnf.0000000000000346] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
33 Grange C, Gurrieri M, Verta R, Fantozzi R, Pini A, Rosa AC. Histamine in the kidneys: what is its role in renal pathophysiology? Br J Pharmacol 2020;177:503-15. [PMID: 30741418 DOI: 10.1111/bph.14619] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
34 Krief S, Berrebi-Bertrand I, Nagmar I, Giret M, Belliard S, Perrin D, Uguen M, Robert P, Lecomte JM, Schwartz JC, Finance O, Ligneau X. Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol. Pharmacol Res Perspect 2021;9:e00855. [PMID: 34423920 DOI: 10.1002/prp2.855] [Reference Citation Analysis]
35 Podlewska S, Latacz G, Łażewska D, Kieć-kononowicz K, Handzlik J. In silico and in vitro studies on interaction of novel non-imidazole histamine H3R antagonists with CYP3A4. Bioorganic & Medicinal Chemistry Letters 2020;30:127147. [DOI: 10.1016/j.bmcl.2020.127147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Bolin K, Niska PÅ, Pirhonen L, Wasling P, Landtblom AM. The cost utility of pitolisant as narcolepsy treatment. Acta Neurol Scand 2020;141:301-10. [PMID: 31838740 DOI: 10.1111/ane.13202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
37 Mocking TAM, Verweij EWE, Vischer HF, Leurs R. Homogeneous, Real-Time NanoBRET Binding Assays for the Histamine H3 and H4 Receptors on Living Cells. Mol Pharmacol 2018;94:1371-81. [PMID: 30249614 DOI: 10.1124/mol.118.113373] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
38 Lehert P, Szoeke C. Comparison of modafinil and pitolisant in narcolepsy: a non-inferiority meta-analytical approach. Drugs Context 2020;9:2020-6-2. [PMID: 32699548 DOI: 10.7573/dic.2020-6-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
39 Wágner G, Mocking TAM, Kooistra AJ, Slynko I, Ábrányi-Balogh P, Keserű GM, Wijtmans M, Vischer HF, de Esch IJP, Leurs R. Covalent Inhibition of the Histamine H3 Receptor. Molecules 2019;24:E4541. [PMID: 31835873 DOI: 10.3390/molecules24244541] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Pérez-carbonell L. Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy. Curr Treat Options Neurol 2019;21. [DOI: 10.1007/s11940-019-0595-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
41 Hauwert NJ, Mocking TAM, Da Costa Pereira D, Lion K, Huppelschoten Y, Vischer HF, De Esch IJP, Wijtmans M, Leurs R. A Photoswitchable Agonist for the Histamine H3 Receptor, a Prototypic Family A G-Protein-Coupled Receptor. Angew Chem Int Ed Engl 2019;58:4531-5. [PMID: 30735597 DOI: 10.1002/anie.201813110] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
42 Alachkar A, Łażewska D, Latacz G, Frank A, Siwek A, Lubelska A, Honkisz-Orzechowska E, Handzlik J, Stark H, Kieć-Kononowicz K, Sadek B. Studies on Anticonvulsant Effects of Novel Histamine H3R Antagonists in Electrically and Chemically Induced Seizures in Rats. Int J Mol Sci 2018;19:E3386. [PMID: 30380674 DOI: 10.3390/ijms19113386] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
43 Moriguchi T, Takai J. Histamine and histidine decarboxylase: Immunomodulatory functions and regulatory mechanisms. Genes Cells 2020;25:443-9. [PMID: 32394600 DOI: 10.1111/gtc.12774] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
44 Obara I, Telezhkin V, Alrashdi I, Chazot PL. Histamine, histamine receptors, and neuropathic pain relief. Br J Pharmacol 2020;177:580-99. [PMID: 31046146 DOI: 10.1111/bph.14696] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 11.3] [Reference Citation Analysis]
45 Łażewska D, Kaleta M, Hagenow S, Mogilski S, Latacz G, Karcz T, Lubelska A, Honkisz E, Handzlik J, Reiner D, Satała G, Filipek B, Stark H, Kieć-kononowicz K. Novel naphthyloxy derivatives – Potent histamine H3 receptor ligands. Synthesis and pharmacological evaluation. Bioorganic & Medicinal Chemistry 2018;26:2573-85. [DOI: 10.1016/j.bmc.2018.04.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
46 Provensi G, Passani MB, Costa A, Izquierdo I, Blandina P. Neuronal histamine and the memory of emotionally salient events. Br J Pharmacol 2020;177:557-69. [PMID: 30110713 DOI: 10.1111/bph.14476] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
47 Lehert P, Falissard B. Multiple treatment comparison in narcolepsy: a network meta-analysis. Sleep 2018;41. [PMID: 30239930 DOI: 10.1093/sleep/zsy185] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
48 Dauvilliers Y, Arnulf I, Szakacs Z, Leu-Semenescu S, Lecomte I, Scart-Gres C, Lecomte JM, Schwartz JC; HARMONY III study group. Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study. Sleep 2019;42:zsz174. [PMID: 31529094 DOI: 10.1093/sleep/zsz174] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 14.5] [Reference Citation Analysis]
49 Shan L, Fronczek R, Lammers GJ, Swaab DF. The tuberomamillary nucleus in neuropsychiatric disorders. Handb Clin Neurol 2021;180:389-400. [PMID: 34225943 DOI: 10.1016/B978-0-12-820107-7.00024-0] [Reference Citation Analysis]
50 Thorpy MJ, Bogan RK. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. Sleep Med 2020;68:97-109. [PMID: 32032921 DOI: 10.1016/j.sleep.2019.09.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]